-+ 0.00%
-+ 0.00%
-+ 0.00%

MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs

Benzinga·07/21/2026 12:06:37
Listen to the news

MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.

The license provides Genentech with access to MaxCyte’s ExPERT GTx® platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering.